An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Cevostamab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary) ; Tocilizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms CAMMA 1
- Sponsors Genentech
- 17 Jun 2024 Status changed from active, no longer recruiting to recruiting.
- 14 Jun 2024 Planned End Date changed from 15 Jul 2025 to 1 Oct 2026.
- 14 Jun 2024 Status changed from completed to active, no longer recruiting.